These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29280108)

  • 1. CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
    Barber TJ; Imaz A; Boffito M; Niubó J; Pozniak A; Fortuny R; Alonso J; Davies N; Mandalia S; Podzamczer D; Gazzard B
    J Neurovirol; 2018 Feb; 24(1):98-105. PubMed ID: 29280108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C.
    Pujari S; Gaikwad S; Bele V; Joshi K; Dabhade D
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218759211. PubMed ID: 29473485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
    Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
    Macías J; Recio E; Márquez M; García C; Jiménez P; Merino D; Muñoz L; Pasquau J; Ojeda G; Bancalero P; Chueca N; Pineda JA
    HIV Med; 2014 Aug; 15(7):417-24. PubMed ID: 24580801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Huhn GD; Sigman A; Livak B
    Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short Communication: The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study.
    Tiraboschi J; Hamzah L; Teague A; Kulasegaram R; Post F; Jendruleck I; Murray T; Fox J
    AIDS Res Hum Retroviruses; 2016 Dec; 32(12):1198-1201. PubMed ID: 27216134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.
    Rossetti B; Gagliardini R; Sterrantino G; Colangeli V; Latini A; Colafigli M; Vignale F; Rusconi S; Di Biagio A; Orofino G; Mezzaroma I; Vullo V; Francisci D; Mastroianni C; Trezzi M; Canovari B; Lamonica S; Ciccullo A; Borghetti A; DʼArminio Monforte A; Di Giambenedetto S; De Luca A;
    J Acquir Immune Defic Syndr; 2019 May; 81(1):e17-e21. PubMed ID: 30789452
    [No Abstract]   [Full Text] [Related]  

  • 10. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
    Bartels H; Decosterd L; Battegay M; Marzolini C
    J Antimicrob Chemother; 2017 Sep; 72(9):2574-2577. PubMed ID: 28575323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.
    Gutierrez-Valencia A; Trujillo-Rodriguez M; Fernandez-Magdaleno T; Espinosa N; Viciana P; López-Cortés LF
    J Int AIDS Soc; 2018 Feb; 21(2):. PubMed ID: 29430854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues.
    Antinori A; Clarke A; Svedhem-Johansson V; Arribas JR; Arenas-Pinto A; Fehr J; Gerstoft J; Horban A; Clotet B; Ripamonti D; Girard PM; Hill AM; Moecklinghoff C
    AIDS; 2015 Sep; 29(14):1811-20. PubMed ID: 26372387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
    Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
    HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).
    Gianotti N; Galli L; Maserati R; Sighinolfi L; Ripamonti D; Palvarini L; Lo Caputo S; Focà E; Celesia BM; Baldelli F; Sterrantino G; Lazzarin A
    New Microbiol; 2016 Oct; 39(4):290-294. PubMed ID: 27551725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
    Delille CA; Pruett ST; Marconi VC; Lennox JL; Armstrong WS; Arrendale RF; Sheth AN; Easley KA; Acosta EP; Vunnava A; Ofotokun I
    J Clin Pharmacol; 2014 Sep; 54(9):1063-71. PubMed ID: 24691856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
    Mena Á; Cid P; Dueñas C; Garcinuño MÁ; Lorenzo JF; Margusino L; Quiñones M; Grande C; Rodríguez-Osorio I; Castro Á
    HIV Clin Trials; 2018 Oct; 19(5):197-201. PubMed ID: 30605006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
    Ahmed N; Okoli C; Ainsworth J
    Int J STD AIDS; 2016 Mar; 27(4):321-2. PubMed ID: 25969439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
    Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G
    BMC Infect Dis; 2017 Sep; 17(1):658. PubMed ID: 28964268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.